RPTX

RPTX

USD

Repare Therapeutics Inc. Common Shares

$1.780-0.040 (-2.198%)

Reaalajas hind

Healthcare
Biotehnoloogia
Kanada

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$1.820

Kõrge

$1.855

Madal

$1.780

Maht

0.15M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

76.5M

Tööstusharu

Biotehnoloogia

Riik

Canada

Kauplemisstatistika

Keskmine maht

0.13M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $0.89Praegune $1.780Kõrge $4.069

Seotud uudised

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $3

HC Wainwright & Co. analyst Robert Burns maintains Repare Therapeutics with a Buy and lowers the price target from $5 to $3.

Vaata rohkem
HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $3
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $3

HC Wainwright & Co. analyst Robert Burns maintains Repare Therapeutics with a Buy and lowers the price target from $5 to $3.

Vaata rohkem
HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $3
BusinessWire

Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy data from the Phase

Vaata rohkem
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics